Cargando…
SARS-CoV-2/COVID-19 in multiple sclerosis patients receiving disease-modifying therapy
At the end of 2019, the COVID-19 pandemic began, which at the time of writing continues to be a serious problem for many areas of medicine, including neurology. Since patients with multiple sclerosis (MS) often exhibit motor disability and receive disease-modifying therapy (DMT), which has an immuno...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831713/ https://www.ncbi.nlm.nih.gov/pubmed/33388661 http://dx.doi.org/10.1016/j.clineuro.2020.106451 |